Previous 10 | Next 10 |
LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate ...
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30...
2023-08-30 16:15:16 ET Summary Ultragenyx Pharmaceutical Inc. shares have declined following Q2 numbers and a broader selloff in the healthcare sector. The company continues to show growth in product sales and progress in its clinical programs for setrusumab. Further catalysts...
2023-08-23 08:47:02 ET VCI Global ( VCIG ) +61% after announces visionary collaboration with Microsoft Azure OpenAI . iTeos Therapeutics ( ITOS ) +37% in reaction as Roche send anti-TIGIT developers higher after mistakenly-released cancer drug data . Arcus ...
2023-08-23 07:31:22 ET More on Roche Roche drives rival anti-TIGIT developers higher after cancer drug data Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender Roche, Alnylam in pact for blood pressure candidate Roivant report...
Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients NOVATO, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical In...
2023-06-06 08:23:18 ET Shares of Ultragenyx Pharmaceutical ( NASDAQ: RARE ) and Mereo BioPharma ( MREO ) gained in the pre-market Tuesday after the biotechs announced mid-stage data for setrusumab, a monoclonal antibody targeted at the bone disorder osteogenesis imperfecta (OI)....
LONDON, May 31, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the...
2023-05-29 05:19:13 ET Summary Mereo BioPharma's focus on rare diseases draws interest, but concerns about setrusumab's efficacy persist. Increased R&D and administrative expenses led to a substantial net loss for Mereo in 2022. The company has reached key milestones, incl...
LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat fo...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
Mereo BioPharma Group Website:
2024-06-20 09:00:06 ET Joseph Schwartz from Leerink Partners issued a price target of $8.00 for MREO on 2024-06-20 07:21:00. The adjusted price target was set to $8.00. At the time of the announcement, MREO was trading at $3.98. The overall price target consensus is at $...
2024-06-14 10:45:03 ET Cleanspark Inc (CLSK) CLSK is trading UP for the last 5 days, and it at trading at $18.30 with volume of 12,068,034 and a one day change of $0.33 (1.84%). Cleanspark Inc has a 52-week low of 3.38 and a 52-week high of $24.72. The business's 50-day moving avera...
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced the pricing of an underwritten offering of 12,531,300 of its American Dep...